Goldman Sachs’s Adial Pharmaceuticals ADIL Stock Holding History

Goldman Sachs’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-31	Closed	-$53K	–	6536
2021 Q4	$53K	Buy	+31	New	+$61K	﹤0.01%	6255

Other funds holding ADIL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

PAG

Private Advisor Group Morristown, New Jersey $21.3B AUM 22.13% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Goldman Sachs's ADIL Position: Q1 2022 in Review

Goldman Sachs sold out of Adial Pharmaceuticals (ADIL) in Q1 2022, closing a stake of 31 shares — an estimated $53K sold.

Goldman Sachs first reported a position in ADIL in Q4 2021 and held it in 1 quarter. The position peaked at $53K in Q4 2021. 22 funds tracked by Wall St. Rank hold ADIL as of Q1 2022.

Goldman Sachs reported no remaining Adial Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Goldman Sachs sold 31 Adial Pharmaceuticals shares in Q1 2022, an estimated $53K.
Goldman Sachs first reported a position in Adial Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Goldman Sachs's Adial Pharmaceuticals position peaked at $53K in Q4 2021.
22 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2022.

Based on Goldman Sachs's 13F filing for Q1 2022, filed 16 May 2022.